Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea's (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights
/PRNewswire/ -- Despite the availability of on-label products to treat diabetic retinopathy (DR), Genentech's off-label option, Avastin, is the predominant...
Source: prnewswire.com